Health Catalyst, Inc.

Health Catalyst, Inc. (HCAT) Market Cap

Health Catalyst, Inc. has a market capitalization of $97.9M.

Financials based on reported quarter end 2025-12-31

Price: $1.33

0.02 (1.53%)

Market Cap: 97.87M

NASDAQ · time unavailable

CEO: Benjamin Albert

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2019-07-25

Website: https://www.healthcatalyst.com

Health Catalyst, Inc. (HCAT) - Company Information

Market Cap: 97.87M · Sector: Healthcare

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.

Analyst Sentiment

68%
Buy

Based on 22 ratings

Analyst 1Y Forecast: $3.67

Average target (based on 4 sources)

Consensus Price Target

Low

$2

Median

$3

High

$3

Average

$3

Potential Upside: 88.0%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 HEALTH CATALYST INC (HCAT) — Investment Overview

🧩 Business Model Overview

Health Catalyst operates in healthcare analytics—delivering software and implementation services that help provider and payer organizations measure performance, improve clinical outcomes, and manage cost. The value chain is characterized by (1) discovery and workflow mapping, (2) data connectivity and governance across clinical and operational systems, (3) deployment of analytics modules and quality/performance measures, and (4) ongoing optimization through training, support, and continuous improvement.

Customer stickiness is driven by embedding analytics into day-to-day care delivery and operational reporting: once clinical, operational, and governance workflows are integrated, extracting the solution becomes costly both financially (re-implementation) and operationally (lost process knowledge and reporting continuity). This creates a “usage + outcomes” loop where adoption typically deepens over time as teams expand to additional measures, service lines, and geographies.

💰 Revenue Streams & Monetisation Model

The monetisation model combines software subscriptions with services. Software revenue is typically recurring and supports gross margin expansion as customers mature in deployment and usage. Services revenue is primarily implementation- and optimization-oriented, including onboarding, configuration, analytics development, data integration, and training.

Margin drivers are centered on:

  • Recurring software mix: Higher subscription/service-to-software conversion tends to improve business quality over the cycle.
  • Scalability of deployments: Reusable templates, measure libraries, and repeatable implementation patterns reduce incremental delivery effort.
  • Client expansion: Growth beyond initial units (more departments, sites, and measures) increases average revenue per customer with limited incremental sales overhead.

🧠 Competitive Advantages & Market Positioning

Health Catalyst’s most defensible advantage is workflow-embedded switching costs supported by data and intangible assets. While competitors can offer point analytics tools, Health Catalyst’s differentiation typically comes from how analytics is operationalized—data governance, standardized performance measures, and implementation methodology integrated into healthcare delivery processes.

  • Switching costs (hard): Moving away requires rebuilding data pipelines, re-establishing governance, and re-training clinical and operations teams. The solution is not merely a dashboard—it is a process layer for measurement and improvement.
  • Intangible assets (hard): Domain-specific measure frameworks, implementation playbooks, and accumulated knowledge from deployments contribute to delivery efficiency and faster time-to-value.
  • Economic alignment tailwinds: In value-based care and quality measurement environments, analytics that improves performance and reporting becomes an ongoing operational requirement, not a one-off project.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by structural demand for measurement, accountability, and risk/cost management in healthcare. The most durable drivers include:

  • Ongoing shift toward value-based payment: Incentives increasingly reward quality and efficiency, requiring robust clinical and operational analytics.
  • Healthcare data complexity: Providers and payers face fragmentation across EHRs, claims, labs, and operational systems. Governance and integration create sustained demand for analytics platforms that can standardize performance measurement.
  • Quality reporting and compliance: Measurement requirements across clinical programs create a long-duration need for data integrity, reporting automation, and auditability.
  • Expansion within accounts: Initial deployments often cover high-priority clinical pathways; subsequent rollout across additional lines of service and geographies supports durable, compounding revenue.

The relevant TAM is broad across U.S. and other markets where providers and payers participate in quality programs, value-based arrangements, and mandated reporting—though penetration is constrained by implementation capacity and the time required to integrate data and operational workflows.

⚠ Risk Factors to Monitor

  • Implementation and adoption risk: Analytics value depends on data readiness, clinical/operational workflow change, and sustained use. Under-adoption can reduce expansion rates and inflate services dependency.
  • Budget cyclicality and customer concentration: Healthcare IT spending can be sensitive to reimbursement dynamics, operating margins, and procurement cycles at large customers.
  • Regulatory and privacy/security requirements: Healthcare data handling is subject to evolving privacy, security, and compliance regimes. Breaches or non-compliance can create material operational and legal exposure.
  • Competitive pressure from broader platforms: EHR vendors and cloud data/analytics ecosystems can integrate analytics features. The key question is whether Health Catalyst retains differentiation through deeper workflow embedding and governance rather than feature parity.
  • Technology transitions: Shifts in data infrastructure (cloud migration, data standards, interoperability frameworks) may require continual platform and integration investment.

📊 Valuation & Market View

Equity markets often value healthcare analytics and software businesses on a blend of SaaS-like metrics and profitability trajectory. Common reference points include:

  • EV/Revenue or EV/ARR: Reflects recurring revenue quality and expectations for customer expansion and retention.
  • EV/EBITDA or gross margin profile: Captures operating leverage as implementation delivery scales and software mix increases.
  • Contract duration and net retention signals: Market focus typically emphasizes retention, expansion, and the proportion of recurring revenue.

The valuation “needle movers” tend to be sustainable growth in recurring software, evidence of expanding utilization within installed accounts, and improving operating leverage as delivery models mature. In this sector, durability of renewals and the ability to convert services work into repeatable, scalable software-led outcomes commonly drive rerating.

🔍 Investment Takeaway

Health Catalyst presents a long-term thesis grounded in healthcare’s structural need for measurement and performance improvement. The core moat is workflow-embedded switching costs reinforced by domain-specific intangible assets and recurring software economics. With the market continuing to emphasize value-based care, quality reporting, and cost management, the company is positioned to benefit from multi-year account expansion—provided it sustains adoption, manages implementation complexity, and maintains differentiation against platform-based entrants.


⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"HCAT reported revenue of $74.68M and a net loss of $91.03M for the fiscal period ending December 31, 2025. The firm has total assets of $502.64M against liabilities of $256.86M, resulting in equity of $245.78M. Despite generating operating cash flow of $9.91M and maintaining a free cash flow of $9.64M, the company still faces significant challenges with profitability, highlighted by negative net income and a substantial price decline of 75.34% over the past year. The company's leverage appears manageable with a net debt of -$31.2M, indicating cash reserves exceed debt obligations. However, consistent losses and declining market performance, alongside a lack of dividends, present risks. Analyst price targets indicate a potential upside but reflect skepticism given the current performance. The outlook requires careful attention as HCAT navigates growth and profitability issues against a backdrop of ongoing market volatility."

Revenue Growth

Caution

Moderate revenue generation but faced with net losses.

Profitability

Neutral

Negative net income and substantial losses significantly affect ratings.

Cash Flow Quality

Fair

Positive free cash flow indicates some operational strength.

Leverage & Balance Sheet

Neutral

Manageable debt levels with positive equity but needs scrutiny.

Shareholder Returns

Neutral

Large price drop over the past year and no dividends paid.

Analyst Sentiment & Valuation

Caution

Mixed analyst ratings suggest cautious sentiment and potential for recovery.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management’s tone is deliberately constrained: no full-year 2026 guidance, citing an “assessment mode” and the financial impact of operational changes. The Q&A confirms why. The dominant hurdle is DOS to Ignite migration, with explicit dollar and timing pressure—Q1 revenue is guided down to $68M-$70M with adjusted EBITDA of $7M-$8M, including ~$1.5M data-platform revenue pressure and ~$2.0M TEMS downselling. Beyond the near term, management flagged ~$12.5M DOS-related ARR downsell/churn for 2026-2027 (expect ~75% to hit 2026, weighted midyear/late 2026) plus ~$52M more DOS ARR under negotiation (including $35M data platform infrastructure). On the positive side, gross margin expansion is real (+690 bps in Q4 adjusted gross margin to 53.5%) and enterprise application relationships are generally expected to be retained, even as data platform infrastructure faces disintermediation/downsells.

AI IconGrowth Catalysts

  • Technology-led bookings emphasis via sharper commercial approach
  • Differentiated applications tied to cost intelligence, clinical measures/ambulatory strategy, and consumer intelligence
  • Retention improvement through more predictable DOS to Ignite migrations and client value realization

Business Development

  • Client negotiations and plans to retain DOS data platform infrastructure ARR while migrating to Ignite (names not provided)
  • Partners/industry leaders discussed as part of sharpened commercial story (no specific names provided)

AI IconFinancial Highlights

  • FY25 revenue: $311.1M (+1% YoY); Q4 revenue: $74.7M vs $79.6M prior-year
  • FY25 adjusted EBITDA: $41.4M (+59% YoY); Q4 adjusted EBITDA: $13.8M vs $7.9M prior-year
  • Q4 adjusted gross margin: 53.5% vs 46.6% prior-year (+690 bps); FY25 adjusted gross margin: 51.1% (technology GM 67.4%, professional services GM 18.3%)
  • FY25 adjusted operating expenses: $117.7M (38% of revenue) vs $123.4M (40% of revenue) prior-year; Q4 OpEx: $26.2M (35% of revenue) vs $29.2M (37%)
  • Q4 adjusted net income per share: $0.08; FY25 adjusted EPS: $0.19
  • GAAP impairment charges: $110.2M in 2025 (goodwill/intangibles) driving GAAP net loss to $178.0M from $69.5M (2024)
  • Q1 2026 guidance: revenue $68.0M-$70.0M; adjusted EBITDA $7.0M-$8.0M (initial only; full-year guidance deferred)

AI IconCapital Funding

  • Ended FY25 cash, cash equivalents, short-term investments: ~$96.0M
  • Term loan debt outstanding: ~$161.0M
  • No share buyback or new capital raise amounts disclosed in the transcript

AI IconStrategy & Ops

  • Back-to-basics refocus: simplify packaging/go-to-market, reduce complexity, improve predictability of migrations
  • Automation/global resources to reduce time-to-value and eliminate operational complexity
  • In-flight organizational changes: appointed GMs for interoperability and cybersecurity; transition of Chief Commercial Officer; searches for Chief Operating Officer and Chief Marketing Officer
  • Added migration-related personnel/contractors and added R&D investments in AI and India (near-term margin pressure acknowledged)

AI IconMarket Outlook

  • No full-year 2026 guidance yet; management plans to provide full-year revenue and adjusted EBITDA guidance no later than the Q1 earnings call in May
  • Q1 2026 revenue decline drivers (vs Q4 2025):

AI IconRisks & Headwinds

  • DOS to Ignite migration headwind: Q1 2026 revenue down ~$1.5M vs Q4 2025 due to data platform pressure
  • Q1 2026 TEMS-related revenue reduction: ~$2.0M decrease from downselling and further exit of lower-margin TEMS arrangements
  • Non-recurring revenue decrease in Q1 2026: ~$1.5M decline vs Q4 2025 due to project completion/renewal timing
  • DOS-related ARR downsell/churn at risk across 2026-2027: ~$12.5M notified; management expects ~75% of this to impact 2026 (with more impact midyear-late 2026)
  • Additional DOS-related ARR subject to negotiation across 2026-2027: ~$52.0M total; ~$35.0M is estimated data platform infrastructure ARR
  • Highest pressure in data platform infrastructure (hosting) portion of DOS; applications/integrated application relationships expected to be retained more often than data platform infrastructure
  • Margin durability risk: duplicate hosting costs from DOS to Ignite migration and migration personnel impact professional services adjusted gross margin (impact seen in Q1 2026; removal expected after migration)

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the HCAT Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (HCAT)

© 2026 Stock Market Info — Health Catalyst, Inc. (HCAT) Financial Profile